l carnitine and prostate cancer Frontiers Carnitine | Memorial Sloan Kettering
Carnitine Memorial Sloan Kettering Cancer Center Acetyl l carnitine is an anti angiogenic agent targeting the VEGFR2 and CXCR4 pathways ScienceDirect Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy ACS Pharmacology & Translational Science Acetyl L Carnitine downregulates invasion (CXCR4 CXCL12, MMP 9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies Journal of Experimental & Clinical Cancer Research Springer
Pay in 4 interest-free payments of $6.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21



